The world may be closer to knowing why Ebola spreads so easily thanks to a team of researchers from Tulane University and other leading institutions who discovered a new biological activity in a small protein from the deadly virus.
This story starts with a young graduate student in San Diego and leads all the way to Sierra Leone, to a unique hospital where Lassa fever victims arrive by the thousands every year.
With an Ebola outbreak underway in the Democratic Republic of Congo, experts say health care providers should review their Ebola response plans now to avoid repeating past mistakes.
Two groups of researchers at Argonne earned special awards from the office of the U.S. Secretary of Energy for addressing the global health challenges of Ebola and cancer.
Ebola outbreaks are set to be managed quickly and efficiently – saving lives – with a new approach developed by an international team of researchers, including the University of Warwick, which helps to streamline outbreak decision-making.
UT Southwestern Medical Center researchers collaborated with an international team of scientists to achieve a significant milestone in the effort to understand pathogens responsible for some of the world’s most deadly infectious diseases.
Researchers at Sandia National Laboratories just received recognition from the Secretary of Energy for their work to mitigate the effects of the 2014 Ebola epidemic. Reducing the amount of time Liberians who suspected they had Ebola spent waiting in large, open waiting rooms called Ebola treatment units was critical to controlling the outbreak. Sandia modeled and analyzed the West Africa nation’s blood sample transport system from the treatment units to diagnostic labs and made recommendations to improve turnaround time.
The 2014–2015 Ebola epidemic affected several countries in West Africa, leading to the death of more than 11'000 people. Although this epidemic of Ebolavirus disease is over, there is no knowing if, when or where another may strike. It is therefore more important than ever to find a reliable vaccine against this deadly disease. Research on vaccines, which was ongoing during the epidemic in West Africa, is now yielding promising results.
Many people might not have heard of the Aedes aegypti mosquito until this past year, when the mosquito, and the disease it can carry – Zika – began to make headlines. But more than 220 years ago, this same breed of mosquito was spreading a different and deadly epidemic right here in Philadelphia and just like Zika, this epidemic is seeing a modern resurgence, with Brazil at its epicenter.
An international effort to analyze the entire database of Ebola virus genomes from the 2013-2016 West African epidemic reveals insights into factors that sped or slowed the rampage and calls for using real-time sequencing and data-sharing to contain future viral disease outbreaks.
Dr. Robert Davey, Scientist at Texas Biomedical Research Institute, is part of a team of researchers working to find new drugs that will stop Ebola virus from growing inside infected cells. Dr. Christopher Basler, a professor in the Institute for Biomedical Sciences at Georgia State University, has received a five-year, $4.1 million federal grant for this project.
Ecologists at the University of Georgia have developed a model that maps the likelihood of Ebola virus “spillovers”—when the virus jumps from its long-term host to humans or animals such as great apes—across Africa on a month-by-month basis.
As the Zika virus continues to spread rapidly across the globe, it might pose a particular risk to people previously infected with two related viruses, dengue and West Nile, researchers at the Icahn School of Medicine at Mount Sinai have found. Their study, published in the journal Science, may help explain the severe manifestations of Zika virus infection observed in specific populations, including those in South America.
Dr. Christopher Basler, a professor in the Institute for Biomedical Sciences at Georgia State University, director of the university’s Center for Microbial Pathogenesis and a Georgia Research Alliance Eminent Scholar in Microbial Pathogenesis, has received a five-year, $4.1 million federal grant to develop a drug targeting Ebola virus.
Supplemental funding will allow three partner institutions to perform additional site visits, conduct more education and training courses, as well as build a special pathogens research network.
An international group of researchers associated with the World Health Organization has published its final report on the Ebola vaccine trial in Guinea, finding that the vaccine is a safe and effective way to prevent Ebola infection.
An experimental Ebola vaccine was highly protective against the deadly virus in a major trial in Guinea, according to a new study that included researchers from the University of Maryland School of Medicine.
The National Center for Advancing Translational Sciences (NCATS) recently awarded $596,533.00 to Collaborations Pharmaceuticals, Inc. (CPI) to initiate a partnership with Texas Biomedical Research Institute aimed at repurposing an antimalarial for use against the Ebola virus.
A new study co-led by scientists at The Scripps Research Institute (TSRI) suggests that Ebola virus gained a genetic mutation during the 2013–16 epidemic that appears to have helped it better target human cells.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right